Ethica Group assisted 21 Invest, in the acquisition of a majority stake in Omega Pharma, a leading Italian company in production and distribution of food supplements.

Omega Pharma is today a point of reference for the nutraceutical market in terms of innovation, quality and scientific content of its products. The company specializes in various therapeutic areas, such as angiology, gastroenterology, urology, gynecology, ophthalmology and paediatrics, characterized by interesting growth dynamics.

The sales force has over 130 medical representatives throughout the country and is a point of reference for medical specialists in the various therapeutic areas. Omega Pharma generates a turnover of over 20 million euros with an average annual growth of 15% over the last 10 years. Omega Pharma’s sales develop mainly in the pharmacy channel, especially in Italy but with a growing trend internationally.

The nutraceutical sector is characterized by long-term growth drivers, such as the aging of the population and the new generations’ awareness of the importance of prevention for maintaining the health of the body and the immune system. The Italian nutraceutical market is the main one in Europe, with significant growth dynamics and a strong propensity for innovation, fueled by the various excellences active in the territory.

The Italian team of 21 Invest will integrate the entrepreneurial tradition of the founding family with its skills and strategic approach developed over 30 years of activity, to allow Omega Pharma to undertake an ambitious growth path to become a leader in the sector. Gianantonio Tomaselli, CEO and founder of Omega Pharma will continue to lead the development path and will maintain a 35% stake in the company.

The future strategy will in fact be aimed on the one hand at strengthening organic growth, through the improvement of performance in Italy and the expansion in international markets, and on the other at the creation of a platform for consolidation of the market, still very fragmented and rich in opportunities to extend know-how and create synergies.

“Building new industrial champions is our main challenge – comments Alessandro Benetton, President and Founder of 21 Invest – in Omega Pharma we have identified an entrepreneurial reality of excellence, focused on technological research and development and with high professional profiles. With them we aim to develop an ambitious project to consolidate the food supplements sector”.